Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tulrampator - RespireRx Pharmaceuticals/Servier

Drug Profile

Tulrampator - RespireRx Pharmaceuticals/Servier

Alternative Names: Ampakine-CX-1632; CX-1632; S47445

Latest Information Update: 11 Mar 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cortex Pharmaceuticals
  • Developer ADIR; RespireRx Pharmaceuticals; Servier
  • Class Antidementias; Small molecules
  • Mechanism of Action AMPA receptor modulators; Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Major depressive disorder
  • No development reported Dementia; Mild cognitive impairment

Most Recent Events

  • 29 Jan 2018 Chemical structure information added
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Alzheimer's-disease in France (PO, Tablet)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Dementia in France (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top